Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
BELLICUM PHARMACEUTICALS, INC (BLCM)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
12/12/2022 |
8-K
| Quarterly results |
12/07/2022 |
8-K
| Quarterly results |
11/10/2022 |
8-K
| Quarterly results |
08/11/2022 |
8-K
| Quarterly results |
06/16/2022 |
8-K
| Quarterly results |
05/12/2022 |
8-K
| Quarterly results |
03/24/2022 |
8-K
| Quarterly results |
02/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
12/13/2021 |
8-K
| Quarterly results |
12/09/2021 |
8-K
| Quarterly results |
12/06/2021 |
8-K
| Quarterly results |
11/04/2021 |
8-K
| Quarterly results |
09/10/2021 |
8-K
| Investor presentation |
08/12/2021 |
8-K
| Quarterly results |
06/17/2021 |
8-K
| Quarterly results |
05/17/2021 |
8-K
| Quarterly results |
05/07/2021 |
8-K
| Quarterly results |
03/30/2021 |
8-K
| Quarterly results |
02/09/2021 |
8-K
| Quarterly results |
01/08/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
11/27/2020 |
8-K
| Quarterly results |
11/05/2020 |
8-K
| Quarterly results |
11/02/2020 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and between Bellicum Pharmaceuticals and H.C. Wainwright & Co",
"Form of pre-funded warrant",
"Form of warrant to purchase common stock",
"Opinion of Cooley LLP",
"Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market October 29, 2020 17:16 ET | Source: Bellicum Pharmaceuticals, Inc. HOUSTON, Oct. 29, 2020 — Bellicum Pharmaceuticals, Inc. , a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum..." |
|
10/29/2020 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
09/16/2020 |
8-K/A
| Submission of Matters to a Vote of Security Holders Interactive Data |
09/16/2020 |
8-K
| Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhib... |
08/06/2020 |
8-K
| Quarterly results |
06/23/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/17/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles o... |
05/07/2020 |
8-K
| Quarterly results |
05/01/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
04/13/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|